These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 29027832)

  • 21. Safety and pharmacodynamics of venetoclax (ABT-199) in a randomized single and multiple ascending dose study in women with systemic lupus erythematosus.
    Lu P; Fleischmann R; Curtis C; Ignatenko S; Clarke SH; Desai M; Wong SL; Grebe KM; Black K; Zeng J; Stolzenbach J; Medema JK
    Lupus; 2018 Feb; 27(2):290-302. PubMed ID: 28691866
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.
    Davids MS; Roberts AW; Seymour JF; Pagel JM; Kahl BS; Wierda WG; Puvvada S; Kipps TJ; Anderson MA; Salem AH; Dunbar M; Zhu M; Peale F; Ross JA; Gressick L; Desai M; Kim SY; Verdugo M; Humerickhouse RA; Gordon GB; Gerecitano JF
    J Clin Oncol; 2017 Mar; 35(8):826-833. PubMed ID: 28095146
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Venetoclax does not prolong the QT interval in patients with hematological malignancies: an exposure-response analysis.
    Freise KJ; Dunbar M; Jones AK; Hoffman D; Enschede SL; Wong S; Salem AH
    Cancer Chemother Pharmacol; 2016 Oct; 78(4):847-53. PubMed ID: 27586967
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metabolism and Disposition of a Novel B-Cell Lymphoma-2 Inhibitor Venetoclax in Humans and Characterization of Its Unusual Metabolites.
    Liu H; Michmerhuizen MJ; Lao Y; Wan K; Salem AH; Sawicki J; Serby M; Vaidyanathan S; Wong SL; Agarwal S; Dunbar M; Sydor J; de Morais SM; Lee AJ
    Drug Metab Dispos; 2017 Mar; 45(3):294-305. PubMed ID: 27993930
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The utility of in vitro data in making accurate predictions of human P-glycoprotein-mediated drug-drug interactions: a case study for AZD5672.
    Elsby R; Gillen M; Butters C; Imisson G; Sharma P; Smith V; Surry DD
    Drug Metab Dispos; 2011 Feb; 39(2):275-82. PubMed ID: 21075975
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bayesian Population Model of the Pharmacokinetics of Venetoclax in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from the Phase III MURANO Study.
    Deng R; Gibiansky L; Lu T; Agarwal P; Ding H; Li X; Kshirsagar S; Lu D; Li C; Girish S; Wang J; Boyer M; Humphrey K; Freise KJ; Salem AH; Seymour JF; Kater AP; Miles D
    Clin Pharmacokinet; 2019 Dec; 58(12):1621-1634. PubMed ID: 31209657
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mechanistic Physiologically Based Pharmacokinetic Modeling of the Dissolution and Food Effect of a Biopharmaceutics Classification System IV Compound-The Venetoclax Story.
    Emami Riedmaier A; Lindley DJ; Hall JA; Castleberry S; Slade RT; Stuart P; Carr RA; Borchardt TB; Bow DAJ; Nijsen M
    J Pharm Sci; 2018 Jan; 107(1):495-502. PubMed ID: 28993217
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers.
    Ding R; Tayrouz Y; Riedel KD; Burhenne J; Weiss J; Mikus G; Haefeli WE
    Clin Pharmacol Ther; 2004 Jul; 76(1):73-84. PubMed ID: 15229466
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of lapatinib on oral digoxin absorption in patients.
    Koch KM; Smith DA; Botbyl J; Arya N; Briley LP; Cartee L; White JH; Beyer J; Dar MM; Chung HC; Chu Q; Bang YJ
    Clin Pharmacol Drug Dev; 2015 Nov; 4(6):449-53. PubMed ID: 27137717
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Model-Informed Dosing of Venetoclax in Healthy Subjects: An Exposure-Response Analysis.
    Dave N; Gopalakrishnan S; Mensing S; Salem AH
    Clin Transl Sci; 2019 Nov; 12(6):625-632. PubMed ID: 31268229
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of the B-Cell Lymphoma 2 (Bcl-2) Inhibitor Venetoclax in Female Subjects with Systemic Lupus Erythematosus.
    Minocha M; Zeng J; Medema JK; Othman AA
    Clin Pharmacokinet; 2018 Sep; 57(9):1185-1198. PubMed ID: 29333561
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Exposure-response evaluations of venetoclax efficacy and safety in patients with non-Hodgkin lymphoma.
    Parikh A; Gopalakrishnan S; Freise KJ; Verdugo ME; Menon RM; Mensing S; Salem AH
    Leuk Lymphoma; 2018 Apr; 59(4):871-879. PubMed ID: 28797193
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of Rolapitant Administered Intravenously or Orally on the Pharmacokinetics of Digoxin (P-glycoprotein Substrate) and Sulfasalazine (Breast Cancer Resistance Protein Substrate) in Healthy Volunteers.
    Wang X; Zhang ZY; Arora S; Hughes L; Wang J; Powers D; Christensen J; Lu S; Kansra V
    J Clin Pharmacol; 2018 Feb; 58(2):202-211. PubMed ID: 28906558
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia.
    Freise KJ; Jones AK; Eckert D; Mensing S; Wong SL; Humerickhouse RA; Awni WM; Salem AH
    Clin Pharmacokinet; 2017 May; 56(5):515-523. PubMed ID: 27638334
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy.
    Freise KJ; Jones AK; Menon RM; Verdugo ME; Humerickhouse RA; Awni WM; Salem AH
    Hematol Oncol; 2017 Dec; 35(4):679-684. PubMed ID: 27982454
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Venetoclax for the treatment of chronic lymphocytic leukemia.
    Gentile M; Petrungaro A; Uccello G; Vigna E; Recchia AG; Caruso N; Bossio S; De Stefano L; Palummo A; Storino F; Martino M; Morabito F
    Expert Opin Investig Drugs; 2017 Nov; 26(11):1307-1316. PubMed ID: 28972395
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clarithromycin, Midazolam, and Digoxin: Application of PBPK Modeling to Gain New Insights into Drug-Drug Interactions and Co-medication Regimens.
    Moj D; Hanke N; Britz H; Frechen S; Kanacher T; Wendl T; Haefeli WE; Lehr T
    AAPS J; 2017 Jan; 19(1):298-312. PubMed ID: 27822600
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Simultaneous measurement of in vivo P-glycoprotein and cytochrome P450 3A activities.
    Kirby B; Kharasch ED; Thummel KT; Narang VS; Hoffer CJ; Unadkat JD
    J Clin Pharmacol; 2006 Nov; 46(11):1313-9. PubMed ID: 17050796
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of green tea catechins on the pharmacokinetics of digoxin in humans.
    Kim TE; Shin KH; Park JE; Kim MG; Yun YM; Choi DH; Kwon KJ; Lee J
    Drug Des Devel Ther; 2018; 12():2139-2147. PubMed ID: 30022812
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Commonly used surfactant, Tween 80, improves absorption of P-glycoprotein substrate, digoxin, in rats.
    Zhang H; Yao M; Morrison RA; Chong S
    Arch Pharm Res; 2003 Sep; 26(9):768-72. PubMed ID: 14560928
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.